Showing results (161-170 of 412) with videos related to

Sort By:
Pageof 42
Leukemia Research|September 11, 2010
Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia/lymphomaBrady Beltran, Pilar Quiñones, Domingo Morales, et al.
American Journal of Hematology|December 24, 2019
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemiaJorge J Castillo, Joshua N Gustine, Andrew Keezer, et al.
British Journal of Haematology|February 19, 2014
Viral lymphomagenesis: from pathophysiology to the rationale for novel therapiesJorge J Castillo, John L Reagan, Kenneth D Bishop, et al.
Cancers|June 26, 2025
The Genetic and Epigenetic Alterations of Plasmablastic Lymphoma: A Narrative ReviewMichele Bibas, Andrea Antinori, Valentina Mazzotta, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2013
Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administrationSteven P Treon, Christina K Tripsas, Bryan T Ciccarelli, et al.
Blood Advances|November 8, 2018
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemiaZachary R Hunter, Lian Xu, Nickolas Tsakmaklis, et al.
British Journal of Haematology|May 28, 2011
Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimenSteven P Treon, Christina Hanzis, Robert J Manning, et al.
Clinical Lymphoma|March 30, 2005
Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemiaSophia Adamia, Steven P Treon, Tony Reiman, et al.
Blood|January 24, 2018
Extracellular vesicle-mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signalingMateja Manček-Keber, Duško Lainšček, Mojca Benčina, et al.
Biologics : Targets & Therapy|August 27, 2009
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasiasAldo M Roccaro, Irene M Ghobrial, Simona Blotta, et al.
Pageof 42